CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
Dong-A ST stated that its R&D expertise has been reaffirmed by the positive CHMP opinion, following the FDA approval for ...
GlobalData on MSN5d
Lilly touts Omvoh’s superiority over J&J’s Stelara in Crohn’s
Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...
FiercePharma6d
Johnson & Johnson eases initial Stelara blows with strong Darzalex, Carvykti growth
Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...
BioSpace6d
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth
J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and ...
Accord Healthcare receives positive CHMP opinion for IMULDOSA, ustekinumab biosimilar to Stelara
PRNewswire Ahmedabad Gujarat [India] October 19 Accord Healthcare Limited Accord announces that the Committee for Medicinal ...
dermatologyadvisor3d
FDA Approves Stelara Biosimilar Imuldosa for Some Inflammatory Conditions
The FDA has approved Imuldosa, a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.
Johnson & Johnson Q3 Earnings Review: Nicely Poised For Steady Growth (Upgrade)
Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...
FiercePharma7d
On road to crowded Crohn's disease market, Lilly's Omvoh bests J&J's Stelara in head-to-head study
On a mission to collect a key Crohn’s disease approval and build out its inflammatory bowel disease (IBD) profile, Eli Lilly ...
GlobalData on MSN9d
South Korean company Dong-A ST wins FDA approval for Stelara biosimilar
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Drug Store News6d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
devdiscourse2d
Imuldosa® Gains CHMP Approval as Biosimilar to Stelara® in Europe
Imuldosa®, a biosimilar to Stelara®, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), paving the way for its authorization in Europe. Developed by Accord ...